14:30 Mon 01 Mar 2021
Novacyt S.A. - Liquidity Agreement and Total Voting Rights
Novacyt S.A.
("Novacyt" or the "Company")
Liquidity Agreement Monthly Update and Total Voting Rights
During the period from 1 February to
Total Voting Rights
The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.
For further information, please refer to www.novacyt.com or contact:
Novacyt SA
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto /
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com
FTI Consulting (International)
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com / mary.whittow@fticonsulting.com
FTI Consulting (
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information please refer to the website: www.novacyt.com
Further information on the Liquidity Agreement
On
Shareholder approval was granted at the Shareholders' meeting held on
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE